Pontis Capital
Gerlgasse 2/3, Vienna, 1030, Austria
Overview
PONTIS Capital manages two funds with total commitments of more than EUR 60 million, and is actively investing out of its second fund, PONTIS Growth Capital II (“PGC II”). The focus of PGC II is to invest in small and medium-sized growth companies with Established technology or other competitive advantage Existing proof-of-market in markets with growth potential, Scalable business models, and Headquarters in the DACH region (Germany, Austria, Switzerland)
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- EUCODIS Bioscience
Participated · Equity · Feb 2010
EUCODIS Bioscience develops, customizes, manufactures and markets industrial enzymes to help customers in the chemical, pharmaceutical and food and feed industries make manufacturing processes more efficient, cleaner and to generate products with superior properties. The company has recently expanded its lipases family to 20 enzymes and completed several product launches in 2009. It is expanding manufacturing capacity to keep pace with growing customer demand. Management says revenues will finance a good part of the company’s expenses and investments this year. EUCODIS plans to add new enzyme families to its product portfolio and to accelerate development of international markets, while ramping up sales and marketing efforts. The company is headquartered in Austria and has a subsidiary in Germany.
Team
No current team members are available.